# Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Source: https://onco.cc/trials/nct04374630/  
OnCo record `nct04374630` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Afuresertib run by Laekna Limited, completed.

## Summary

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian is a phase 2 interventional study registered as NCT04374630 by Laekna Limited, with 150 participants enrolled, started 2020-07-07, primary completion reached 2023-10-31. Conditions recorded: Platinum-resistant Ovarian Cancer. Interventions recorded: Paclitaxel, Afuresertib.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04374630
- Phase: 2
- Setting: An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
- Sponsor: Laekna Limited
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT04374630: https://clinicaltrials.gov/study/NCT04374630

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Afuresertib](https://onco.cc/drugs/afuresertib/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04374630.json